Peripheral cancer concept stocks soared

Stimulated by the sharp rise of the peripheral anti-cancer concept stocks, the related concept stocks in the A-share market bucked the trend and showed their strength Analysts pointed out that the concept of anti-cancer is on the surface boosted by the periphery, but there are deep-seated reasons behind it, such as the development of domestic stock economy has brought environmental pollution and rapid aging of the population, China will usher in a period of high incidence of cancer, anti-cancer drugs will usher in a golden period of development and so on Stimulated by the sharp rise of similar peripheral stocks, the anti-cancer concept stocks become more aggressive Since this year, the U.S stocks, which have rewritten the record highs for more than 30 times, have not performed well in the near future However, because novogen and peregrine pharmaceuticals, two anti-cancer concept stocks, soared 210% and 80% in a single day, the anti-cancer concept stocks that caused market debate swept the U.S stock market The stock price of stem cell research company Osiris therapeutics Inc rose 142% in a single day In addition, a few days ago, it was reported that the research team of Peking University on "totipotent stem cells" had a new breakthrough, and was included in the American journal Science Authorities pointed out that this achievement provides a new way for future research and development of artificial organs and tackling major diseases such as cancer Analysts believe that anti-cancer concept stocks are expected to be boosted In the A-share market, some anti-cancer concept stocks are indeed stimulated by relevant news to fight against the market Yesterday, the Shanghai stock index fell nearly 20 points, but Jiangsu Wuzhong (600200) rose 3.4%, Huashen group (000790) rose 1.69%, and Haixin shares (600851) and other stocks also turned red against the market Analysts pointed out that the concept of anti-cancer is on the surface boosted by the periphery, but there are deep-seated reasons behind it For example, the development of domestic economy has brought environmental pollution and rapid aging of the population China will usher in a period of high incidence of cancer, and anti-cancer drugs will usher in a golden development period In fact, since this year, some anti-cancer concept stocks have taken the lead in the market Among them, Xiangxue Pharmaceutical (300147), Jiangsu Wuzhong and Peking University Pharmaceutical (000788) increased by more than 90%, reaching 146.50%, 99.13% and 94.43% respectively But Huashen group, Puluo Pharmaceutical (000739), Yibai Pharmaceutical (600594) and Haixin also increased by more than 50%, 89.32%, 58.89%, 56.78% and 55.66% respectively In addition, Yueyang Xingchang (000819) also increased by more than 30% World Health Organization officials predict that cancer will replace cardiovascular disease as the world's largest cause of death in the next two years In this context, the world anti-cancer drug market is growing rapidly According to the data released by the American pharmaceutical consulting company, in just five years, the sales volume of the global anti-cancer drug market has doubled, greatly exceeding the growth rate of other drugs (including cardiovascular drugs) China will usher in a high incidence rate of cancer At the beginning of this year, the 2012 China cancer registry annual report released by the National Cancer Registry Center said that the incidence of cancer in China is serious, and morbidity and mortality are rising In response to this description is a series of cold data, "one person is diagnosed with cancer every six minutes in the country, 8550 people become cancer patients every day, and one in seven to eight people die of cancer." It is worrying that the surging incidence of cancer has not reached the summit According to Chen Wanqing, deputy director of the National Cancer Registry, "cancer incidence rate and mortality rate in China will continue to rise in the next 10 years It is estimated that by 2020, China will have about 3 million cancer deaths and 6.6 million diseases per year " With the increasing incidence of cancer, in 2003, the Ministry of Health issued the outline of China's cancer prevention and control program (2004-2010), which included strengthening cancer registration as the main content of cancer prevention and control As of 2012, there are 222 cancer registries nationwide, covering a population of about 200 million "Economic development has brought environmental pollution, coupled with rapid aging of the population, all of these factors together, are destined to usher in a period of sustained high incidence of cancer in China." Securities analysts pointed out that in recent years, the high incidence of cancer in China is a comprehensive result of the impact of rapid social development on the environment, population structure and lifestyle In February this year, the Ministry of environmental protection of the people's Republic of China issued the 12th Five Year Plan for prevention and control of chemical environmental risks, which clearly stated that due to the pollution of toxic chemicals, some areas have serious health and social problems such as "cancer villages" Although it is difficult for bad air to be scientifically recognized as the culprit of cancer, statistics from Beijing Cancer Prevention and Control Research Office show that as early as 2007, cancer has surpassed cardio cerebrovascular disease as the first killer of Beijing citizens "Life expectancy was not that long Before cancer happened, people died of other diseases Now, there are more and more people over the age of 70 in China, and the risk of cancer is greatly increased " Chen Wanqing said that Chinese population is still aging, and the incidence rate of cancer will continue to rise In recent years, anticancer drugs are facing a "golden decade" Stimulated by the expansion of market demand, they have entered a new boom cycle The sales of the industry have rebounded significantly, the relationship between supply and demand has been improved, and the profitability of the industry has been steadily improved "Driven by rigid demand, the anticancer drug market shows a strong growth trend, and develops well in the long term." Ding pin, an analyst with Haitong Securities, said that China's pharmaceutical industry is in a stage of rapid growth, and the anti-cancer drug market benefits from the high growth of China's pharmaceutical industry "The pharmaceutical industry, which is in the rising channel as a whole, is bound to drive the vigorous development of the market segment of anticancer drugs." It is understood that at present, there are about 130-150 kinds of anticancer drugs approved for marketing in various countries around the world, and there are about 800 kinds of new anticancer drugs under study but not approved for marketing The use of effective anticancer drugs can help patients to obtain a longer survival time Industry researchers have approved that in recent years, the rising cancer mortality rate in China is forcing relevant medical institutions to accelerate cancer research, and more and more biological companies began to invest in the development of anti-cancer drugs At present, China's leading enterprises in the production of anticancer drugs invest about 8% in R & D, which still has a certain gap with the world's giants, but it is far higher than the average level of 2% of China's pharmaceutical and biological industries In an interview with the investment express, analysts pointed out that as China enters into a period of high cancer incidence, the next 10 years will be the "golden decade" of anti-cancer drugs, and the anti-cancer drug industry contains huge investment opportunities At present, it is a good time to find a bargain to lay out anti-cancer concept stocks Wuzhong (600200), Jiangsu Province Before that, there was news that the company was in the process of researching the national first-class biological anti-cancer drug "recombinant human endostatin injection" phase III clinical trial failed In response, Jiangsu Wuzhong has announced that the company is working on the third phase clinical research of "recombinant human endostatin injection", a national class a new biological anti-cancer drug It is understood that the company's key project, recombinant human endostatin injection, dermatostatin injection, obtained the SFDA phase III clinical trial approval document in February 2011, and officially launched the phase III clinical trial in the Cancer Hospital of the Chinese Academy of Medical Sciences at the end of October of the same year The drug is mainly used in non-small cell lung cancer Industry insiders said that the earnings per share base of Wuzhong is relatively low Once the new drug recombinant human endostatin is listed, the company's performance will have explosive growth In this context, investors should pay close attention to the investment opportunities brought by the progress of the project Huashen group (000790) Co., Ltd is a kind of national innovative drug because of its primary liver cancer drug iodine [131I] metoximab injection (ricardine), which has the title of "A-share anti-cancer first brother" According to reports, ricardine is the world's first gene drug targeted with monoclonal antibodies for the treatment of liver cancer, with independent intellectual property rights for the treatment of advanced liver cancer On June 15 this year, Huashen group announced that the anti-cancer products were supported by the 12th Five Year Plan, a major science and technology special project of "major new drug creation", and have passed the review of the medical ethics committee of Zhongshan Hospital Affiliated to Fudan University Since November 2010, the company has obtained the "phase IV clinical summary report of ricardine", and has carried out multi field and multi direction clinical research on the comprehensive treatment of liver cancer based on ricardine Huatai United pointed out that the company clearly wants to become a health medicine enterprise group with biotechnology as the core At present, the business development of the company is basically in line with the expectation, and the prospect of the biological industry represented by likatine in the future is worth looking forward to Haixin Co., Ltd (600851) is developing antigen sensitized human dendritic cells Haixin Biotechnology Co., Ltd (51% owned by the company) cooperates with Shanghai Second Military Medical University in R & D It is the first independent R & D in China that has been officially approved by the State Food and Drug Administration (SFDA), aiming at APDC therapeutic vaccine for advanced colorectal cancer According to a board announcement released on the evening of June 3 this year, the "antigen sensitized human dendritic cells" (APDC) developed by Haixin biology is a new generation of therapeutic tumor vaccine for colorectal cancer On July 26, 2012, the APDC project was approved by the State Food and Drug Administration for conducting phase clinical trials Analysts believe that the company is the first and only enterprise in China that has completed phase I and phase II clinical dendritic cell tumor biotherapy projects, with a promising future.